
Charles M Beasley Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1793774/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 1997, 154, 457-465.	4.0	862
2	Olanzapine versus Placebo and Haloperidol. Neuropsychopharmacology, 1996, 14, 111-123.	2.8	689
3	Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. Journal of Clinical Psychopharmacology, 1997, 17, 407-418.	0.7	616
4	Olanzapine. Clinical Pharmacokinetics, 1999, 37, 177-193.	1.6	460
5	Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology, 1996, 124, 159-167.	1.5	367
6	Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression BMJ: British Medical Journal, 1991, 303, 685-692.	2.4	313
7	Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 1997, 154, 1248-1254.	4.0	287
8	Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 1997, 7, 125-137.	0.3	247
9	Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry, 1999, 174, 23-30.	1.7	226
10	Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis. American Journal of Psychiatry, 1999, 156, 79-87.	4.0	209
11	Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment. American Journal of Psychiatry, 1998, 155, 1247-1253.	4.0	190
12	Fluoxetine and Adult Suicidality Revisited. Journal of Clinical Psychopharmacology, 2007, 27, 682-686.	0.7	178
13	The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 1997, 26, 41-54.	1.1	171
14	Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia. Neuropsychopharmacology, 2002, 26, 494-504.	2.8	167
15	Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. American Journal of Psychiatry, 1997, 154, 963-969.	4.0	151
16	Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia. Journal of Clinical Psychiatry, 1997, 58, 205-211.	1.1	147
17	Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode. Journal of Clinical Psychopharmacology, 1998, 18, 435-440.	0.7	141
18	Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. British Journal of Psychiatry, 1998, 172, 499-505.	1.7	140

#	Article	IF	CITATIONS
19	Tadalafil has No Detrimental Effect on Human Spermatogenesis or Reproductive Hormones. Journal of Urology, 2003, 170, 887-891.	0.2	128
20	Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research, 1999, 8, 417-426.	1.5	125
21	Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial. Journal of Clinical Psychopharmacology, 2001, 21, 14-20.	0.7	125
22	A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia. Biological Psychiatry, 1998, 43, 803-810.	0.7	124
23	Fluoxetine efficacy in menopausal women with and without estrogen replacement. Journal of Affective Disorders, 1999, 55, 11-17.	2.0	116
24	Fluoxetine in Depressed Patients on Dialysis. International Journal of Psychiatry in Medicine, 1997, 27, 71-80.	0.8	114
25	Olanzapine Versus Placebo and Haloperidol: Quality of Life and Efficacy Results of the North American Double-Blind Trial. Neuropsychopharmacology, 1998, 18, 41-49.	2.8	105
26	Analysis of the QTc Interval During Olanzapine Treatment of Patients With Schizophrenia and Related Psychosis. Journal of Clinical Psychiatry, 2001, 62, 191-198.	1.1	105
27	Olanzapine Plasma Concentrations and Clinical Response in Acutely Ill Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1997, 17, 472-477.	0.7	104
28	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, e1-e21.	1.1	99
29	A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil. European Urology, 2004, 45, 499-509.	0.9	94
30	Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology, 1992, 107, 1-10.	1.5	92
31	When Should a Trial of Fluoxetine for Major Depression Be Declared Failed?. American Journal of Psychiatry, 2003, 160, 734-740.	4.0	91
32	Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT Prolongation, Structure Activity Relationship, and Network Analysis. Pharmaceutical Research, 2006, 23, 1133-1143.	1.7	91
33	Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo. Archives of General Psychiatry, 1998, 55, 334-43.	13.8	90
34	Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clinical Therapeutics, 2000, 22, 1319-1330.	1.1	82
35	A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. Journal of Clinical Psychopharmacology, 2003, 23, 582-594.	0.7	79
36	Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services, 1997, 48, 1571-1577.	1.1	68

#	Article	IF	CITATIONS
37	Olanzapine <i>versus</i> haloperidol in the treatment of schizoaffective disorder. British Journal of Psychiatry, 1999, 174, 15-22.	1.7	65
38	Treatment-Associated Suicidal Ideation and Adverse Effects in an Open, Multicenter Trial of Fluoxetine for Major Depressive Episodes. Psychotherapy and Psychosomatics, 2007, 76, 40-46.	4.0	65
39	Safety of Abrupt Discontinuation of Fluoxetine. Journal of Clinical Psychopharmacology, 1998, 18, 193-197.	0.7	64
40	Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. General Hospital Psychiatry, 1996, 18, 8-13.	1.2	63
41	A General Learning Theory and its Application to Schema Abstraction1. Psychology of Learning and Motivation - Advances in Research and Theory, 1979, 13, 277-318.	0.5	59
42	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, 1040-1046.	1.1	57
43	Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression. Journal of Clinical Psychiatry, 2000, 61, 518-524.	1.1	56
44	Tadalafil Improved Erectile Function at Twenty-Four and Thirty-Six Hours After Dosing in Men With Erectile Dysfunction: US Trial. Journal of Andrology, 2005, 26, 310-318.	2.0	55
45	Efficacy, Adverse Events, and Treatment Discontinuations in Fluoxetine Clinical Studies of Major Depression. Journal of Clinical Psychiatry, 2000, 61, 722-728.	1.1	55
46	Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Research, 2003, 119, 113-123.	1.7	51
47	Fluoxetine in tricyclic refractory major depressive disorder. Journal of Affective Disorders, 1990, 20, 193-200.	2.0	50
48	Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. International Clinical Psychopharmacology, 2003, 18, 39-48.	0.9	50
49	An Integrated Analysis of Acute Treatment-Emergent Extrapyramidal Syndrome in Patients With Schizophrenia During Olanzapine Clinical Trials. Journal of Clinical Psychiatry, 2003, 64, 898-906.	1.1	45
50	Blood Pressure Changes During Short-Term Fluoxetine Treatment. Journal of Clinical Psychopharmacology, 1999, 19, 9-14.	0.7	41
51	Fluoxetine: no association with suicidality in obsessive-compulsive disorder. Journal of Affective Disorders, 1992, 24, 1-10.	2.0	40
52	All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics. Journal of Clinical Psychopharmacology, 2007, 27, 252-258.	0.7	39
53	High-Dose Fluoxetine. Journal of Clinical Psychopharmacology, 1991, 11, 166???174.	0.7	38
54	Absence of a Relationship Between Adverse Events and Suicidality During Pharmacotherapy for Depression. Journal of Clinical Psychopharmacology, 1994, 14, 163???169.	0.7	38

#	Article	IF	CITATIONS
55	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal of Geriatric Psychiatry, 2001, 16, S33-S61.	1.3	35
56	The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine. International Clinical Psychopharmacology, 1993, 8, 261-266.	0.9	32
57	Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5—sildenafil, tadalafil, and vardenafil. European Journal of Pharmacology, 2004, 502, 163-167.	1.7	29
58	The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval. Journal of the American College of Cardiology, 2005, 46, 678-687.	1.2	29
59	Fluoxetine versus amitriptyline in the treatment of major depression. International Clinical Psychopharmacology, 1993, 8, 143-150.	0.9	28
60	Efficacy and Safety of Oral Tadalafil in the Treatment of Men in Canada with Erectile Dysfunction: A Randomized, Doubleâ€Blind, Parallel, Placeboâ€Controlled Clinical Trial. Journal of Sexual Medicine, 2005, 2, 685-698.	0.3	27
61	Fluoxetine not associated with increased aggression in controlled clinical trials. International Clinical Psychopharmacology, 1993, 8, 277-280.	0.9	26
62	Fluoxetine in Medically Stable, Depressed Geriatric Patients. Journal of Clinical Psychopharmacology, 1997, 17, 365-369.	0.7	24
63	Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. Journal of Affective Disorders, 2002, 68, 243-249.	2.0	19
64	Early Symptomatic Worsening During Treatment With Fluoxetine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 52-57.	1.1	19
65	TSH response to TRH and haloperidol response latency in psychoses. Biological Psychiatry, 1988, 24, 423-431.	0.7	18
66	Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. Journal of Psychopharmacology, 2011, 25, 639-645.	2.0	18
67	Is Quality of Life Among Minimally Symptomatic Patients With Schizophrenia Better Following Withdrawal or Continuation of Antipsychotic Treatment?. Journal of Clinical Psychopharmacology, 2006, 26, 40-44.	0.7	13
68	Effects of atomoxetine on the <scp>QT</scp> interval in healthy <scp>CYP2D6</scp> poor metabolizers. British Journal of Clinical Pharmacology, 2013, 75, 549-564.	1.1	12
69	Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Psychological Medicine, 2007, 37, 1585-1593.	2.7	10
70	Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings. Expert Review of Clinical Pharmacology, 2008, 1, 815-839.	1.3	7
71	Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methods. Journal of Biopharmaceutical Statistics, 2019, 29, 516-528.	0.4	7
72	Letter to the editors. Neuropsychopharmacology, 1997, 16, 88-88.	2.8	6

5

#	Article	IF	CITATIONS
73	Response to Letter of Professor Tim Lambert. Australian and New Zealand Journal of Psychiatry, 1999, 33, 121-122.	1.3	6
74	Twenty-Four–Hour Measures of Heart Rate–Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2019, 39, 100-107.	0.7	6
75	Hematologic Reference Ranges in a Population of Patients with Schizophrenia. Journal of Clinical Psychopharmacology, 2000, 20, 653-657.	0.7	6
76	Fluoxetine and Norfluoxetine Plasma Levels After Discontinuing Fluoxetine Therapy. Journal of Clinical Psychopharmacology, 2001, 21, 616-618.	0.7	6
77	Systematic Decrements in QTc between the First and Second Day of Contiguous Daily ECG Recordings under Controlled Conditions. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1116-1127.	0.5	2
78	Reference Limits for Outlier Analyses in Randomized Clinical Trials. Therapeutic Innovation and Regulatory Science, 2017, 51, 683-737.	0.8	2
79	Reply to Dr. Friedman. Journal of Clinical Psychopharmacology, 1992, 12, 220???221.	0.7	1
80	Plasma Olanzapine and Clinical Response. Journal of Clinical Psychopharmacology, 1999, 19, 193-194.	0.7	1
81	Suicidality with Fluoxetine. CNS Drugs, 1998, 9, 513-515.	2.7	0
82	Letter to the Editor. Gastroenterology Nursing, 2009, 32, 424.	0.2	0
83	Fluoxetine Mechanism of Action. Journal of the American Academy of Child and Adolescent Psychiatry, 1991. 30. 849.	0.3	0